| Q34060866 | A progressive declining in the burden of malaria in north-eastern Tanzania |
| Q39142616 | A randomized controlled trial of extended intermittent preventive antimalarial treatment in infants |
| Q28471975 | A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children |
| Q24651173 | Acquired immunity to malaria |
| Q39553413 | Adult deaths and the future: a cause-specific analysis of adult deaths from a longitudinal study in rural Tanzania 2003-2007. |
| Q33293164 | Age interactions in the development of naturally acquired immunity to Plasmodium falciparum and its clinical presentation |
| Q35739071 | Age-dependent IgG subclass responses to Plasmodium falciparum EBA-175 are differentially associated with incidence of malaria in Mozambican children |
| Q35713083 | Analysis of Preventive Interventions for Malaria: Exploring Partial and Complete Protection and Total and Primary Intervention Effects |
| Q34407217 | Anti-malarial drugs and the prevention of malaria in the population of malaria endemic areas |
| Q38399521 | Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial |
| Q39029573 | Can changes in malaria transmission intensity explain prolonged protection and contribute to high protective efficacy of intermittent preventive treatment for malaria in infants? |
| Q24243240 | Chemoprophylaxis and intermittent treatment for preventing malaria in children |
| Q24245420 | Chemoprophylaxis and intermittent treatment for preventing malaria in children |
| Q37032859 | Chloroquine is grossly overdosed and overused but well tolerated in Guinea-bissau |
| Q33224264 | Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana |
| Q36849382 | Coadaptation and malaria control |
| Q33817569 | Community effectiveness of intermittent preventive treatment for infants (IPTi) in rural southern Tanzania |
| Q34960038 | Cost-effectiveness of malaria intermittent preventive treatment in infants (IPTi) in Mozambique and the United Republic of Tanzania |
| Q35228689 | Drug resistance maps to guide intermittent preventive treatment of malaria in African infants |
| Q28473083 | Duration of protection against clinical malaria provided by three regimens of intermittent preventive treatment in Tanzanian infants |
| Q33336570 | Duration of protection against malaria and anaemia provided by intermittent preventive treatment in infants in Navrongo, Ghana |
| Q47859968 | Duration of vaccine efficacy against malaria: 5th year of follow-up in children vaccinated with RTS,S/AS02 in Mozambique |
| Q40279020 | Effect of intermittent preventive treatment for malaria during infancy on serological responses to measles and other vaccines used in the Expanded Programme on Immunization: results from five randomised controlled trials |
| Q37033079 | Effective Antimalarial Chemoprevention in Childhood Enhances the Quality of CD4+ T Cells and Limits Their Production of Immunoregulatory Interleukin 10. |
| Q37600130 | Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials |
| Q35804683 | Efficacy and safety of three regimens for the prevention of malaria in young HIV-exposed Ugandan children: a randomized controlled trial |
| Q37492591 | Existing antimalarial agents and malaria-treatment strategies |
| Q34764404 | Follow-up survey of children who received sulfadoxine-pyrimethamine for intermittent preventive antimalarial treatment in infants |
| Q28469180 | Gametocytaemia after drug treatment of asymptomatic Plasmodium falciparum |
| Q37686622 | Host immunity as a determinant of treatment outcome in Plasmodium falciparum malaria |
| Q39500159 | How is childhood development of immunity to Plasmodium falciparum enhanced by certain antimalarial interventions? |
| Q42406285 | Impact of intermittent preventive treatment with sulfadoxine-pyrimethamine on antibody responses to erythrocytic-stage Plasmodium falciparum antigens in infants in Mozambique |
| Q35330733 | Impact of the RTS,S malaria vaccine candidate on naturally acquired antibody responses to multiple asexual blood stage antigens |
| Q35005101 | Induction of antimalaria immunity by pyrimethamine prophylaxis during exposure to sporozoites is curtailed by parasite resistance |
| Q33430011 | Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children |
| Q43947711 | Intermittent preventive malaria treatment in Tanzanian infants |
| Q37747411 | Intermittent preventive treatment against malaria: an update |
| Q48015023 | Intermittent preventive treatment for malaria control in infants: moving towards evidence-based policy and public health action |
| Q21032527 | Intermittent preventive treatment for malaria in children living in areas with seasonal transmission |
| Q91625196 | Intermittent preventive treatment for malaria in infants |
| Q36094775 | Intermittent preventive treatment in infants as a means of malaria control: a randomized, double-blind, placebo-controlled trial in northern Ghana |
| Q28473566 | Intermittent preventive treatment in infants for the prevention of malaria in rural Western kenya: a randomized, double-blind placebo-controlled trial |
| Q37532595 | Intermittent preventive treatment of malaria in infants: how does it work and where will it work? |
| Q21032450 | Intermittent preventive treatment of malaria in pregnant women and infants: making best use of the available evidence |
| Q91898654 | Intermittent preventive treatment with dihydroartemisinin-piperaquine and risk of malaria following cessation in young Ugandan children: a double-blind, randomised, controlled trial |
| Q34754822 | Iron metabolism and malaria. |
| Q42904997 | Large contractors in Africa: conundrums with malaria chemoprophylaxis |
| Q34534151 | Longitudinal study of urban malaria in a cohort of Ugandan children: description of study site, census and recruitment |
| Q37331599 | Low-level malaria infections detected by a sensitive polymerase chain reaction assay and use of this technique in the evaluation of malaria vaccines in an endemic area |
| Q55878749 | Malaria |
| Q24815604 | Malaria chemoprophylaxis and the serologic response to measles and diphtheria-tetanus-whole-cell pertussis vaccines |
| Q34515124 | Malariometric indices from Iganga, Uganda: baseline characterization in preparation of GMZ2 vaccine trial |
| Q37207985 | Mode of action and choice of antimalarial drugs for intermittent preventive treatment in infants |
| Q33351939 | Modelling the epidemiological impact of intermittent preventive treatment against malaria in infants |
| Q33886209 | Modelling the protective efficacy of alternative delivery schedules for intermittent preventive treatment of malaria in infants and children |
| Q33999559 | Morbidity from malaria in children in the year after they had received intermittent preventive treatment of malaria: a randomised trial |
| Q21999119 | Mosquito-borne Diseases |
| Q37274739 | Novel pfdhps haplotypes among imported cases of Plasmodium falciparum malaria in the United Kingdom |
| Q56835876 | Novel therapies for the prevention of malaria |
| Q35023695 | Parasitostatic effect of maslinic acid. II. Survival increase and immune protection in lethal Plasmodium yoelii-infected mice |
| Q36132032 | Potential Impact of Seasonal Malaria Chemoprevention on the Acquisition of Antibodies Against Glutamate-Rich Protein and Apical Membrane Antigen 1 in Children Living in Southern Senegal |
| Q36403400 | Pre-erythrocytic malaria vaccines: towards greater efficacy |
| Q34993578 | Pregnant women are a reservoir of malaria transmission in Blantyre, Malawi |
| Q47936173 | Prospects of intermittent preventive treatment of adults against malaria in areas of seasonal and unstable malaria transmission, and a possible role for chloroquine |
| Q39029567 | Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial |
| Q28541598 | Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial |
| Q92599701 | RTS,S/AS01E immunization increases antibody responses to vaccine-unrelated Plasmodium falciparum antigens associated with protection against clinical malaria in African children: A case-control study |
| Q38961558 | Reduced efficacy of intermittent preventive treatment of malaria in malnourished children |
| Q36834343 | Review of intermittent preventive treatment for malaria in infants and children |
| Q36530291 | Review: Intermittent preventive treatment--a new approach to the prevention of malaria in children in areas with seasonal malaria transmission |
| Q39326401 | Seasonal carriage of pfcrt and pfmdr1 alleles in Gambian Plasmodium falciparum imply reduced fitness of chloroquine-resistant parasites |
| Q38947658 | Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial |
| Q35779524 | Spatio-Temporal Variations in Malaria Incidence in Children Less than 10 Years Old, Health District of Sokone, Senegal, 2010-2013 |
| Q37288862 | The burden of rabies in Tanzania and its impact on local communities |
| Q35819293 | The effectiveness and perception of the use of sulphadoxine-pyrimethamine in intermittent preventive treatment of malaria in pregnancy programme in Offinso district of Ashanti region, Ghana |
| Q37012062 | The immunological challenges of malaria vaccine development |
| Q27344985 | The impact of IPTi and IPTc interventions on malaria clinical burden - in silico perspectives |
| Q24816798 | The promise and potential challenges of intermittent preventive treatment for malaria in infants (IPTi). |
| Q28731458 | The role of age and exposure to Plasmodium falciparum in the rate of acquisition of naturally acquired immunity: a randomized controlled trial |
| Q36981978 | Therapeutic and prophylactic effect of intermittent preventive anti-malarial treatment in infants (IPTi) from Ghana and Gabon |
| Q100526329 | Transcriptome dynamics of CD4+ T cells during malaria maps gradual transit from effector to memory |
| Q33670134 | Treatment of asymptomatic carriers with artemether-lumefantrine: an opportunity to reduce the burden of malaria? |
| Q36723819 | Treatment of childhood Plasmodium falciparum malaria: current challenges |
| Q36178132 | Varying efficacy of intermittent preventive treatment for malaria in infants in two similar trials: public health implications |
| Q34008911 | WHO policy development processes for a new vaccine: case study of malaria vaccines |
| Q37009065 | What does it take to control malaria? |